Study to Access the Relative Bioavailability of Subcutaneous Dose of Nemolizumab When Administered Via Auto-Injector Versus Dual-Chamber Syringe

NCT05405985 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

192

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: Nemolizumab
DRUG: Nemolizumab

Sponsor

Galderma R&D